Under the agreement, GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East UK. Fill and finish comprises the completion stage of vaccine manufacturing, in which vials are prepared for the final vaccine, before it is packaged and distributed for us.
Novavax’s NVX-CoV2373 vaccine candidate has shown strong efficacy in Phase 3 clinical trials, with data showing that it is 96.4% effective against the original Covid-19 strain and 86.3% effective against the UK variant.